BioLineRx (BLRX) EBIAT (2023 - 2025)
Historic EBIAT for BioLineRx (BLRX) over the last 3 years, with Q3 2025 value amounting to -$977000.0.
- BioLineRx's EBIAT rose 8321.88% to -$977000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $151000.0, marking a year-over-year increase of 10059.14%. This contributed to the annual value of -$19.3 million for FY2024, which is 5942.77% up from last year.
- Per BioLineRx's latest filing, its EBIAT stood at -$977000.0 for Q3 2025, which was up 8321.88% from $3.9 million recorded in Q2 2025.
- BioLineRx's EBIAT's 5-year high stood at $18.5 million during Q2 2023, with a 5-year trough of -$19.5 million in Q4 2023.
- Its 3-year average for EBIAT is -$3.2 million, with a median of -$977000.0 in 2025.
- In the last 5 years, BioLineRx's EBIAT crashed by 9739.01% in 2024 and then skyrocketed by 83663.79% in 2025.
- Quarter analysis of 3 years shows BioLineRx's EBIAT stood at -$19.5 million in 2023, then skyrocketed by 59.28% to -$7.9 million in 2024, then surged by 87.69% to -$977000.0 in 2025.
- Its last three reported values are -$977000.0 in Q3 2025, $3.9 million for Q2 2025, and $5.1 million during Q1 2025.